Safety Study of HepaStem for the Treatment of Urea Cycle Disorders (UCD) and Crigler-Najjar Syndrome (CN) (HEP001)

C

Cellaion

Status and phase

Completed
Phase 2
Phase 1

Conditions

Urea Cycle Disorders
Crigler Najjar Syndrome

Treatments

Biological: HepaStem

Study type

Interventional

Funder types

Industry

Identifiers

NCT01765283
HEP001

Details and patient eligibility

About

The purpose of this study is to assess the safety and to appraise the efficacy of one cycle of Hepastem (Heterologous Human Adult Liver-derived Progenitor Cells, HHALPC) infusions in paediatric patients suffering from CN or UCD. The study duration: 12 months starting from the day of treatment: 6 months active surveillance and 6 months observation post-infusion.

Enrollment

20 patients

Sex

All

Ages

Under 17 years old

Volunteers

No Healthy Volunteers

Inclusion and exclusion criteria

GENERAL:

  1. Subject shows patency of the portal vein and branches, with normal flow velocity in the main portal vein as confirmed by Doppler ultrasound and accessibility of the portal vein, or respectively, accessibility of the umbilical vein.
  2. Subject (if capable of signing) and parents or legal representative have provided a written informed assent/consent.
  3. Female subjects of childbearing potential need to have a negative pregnancy test and must agree to use an acceptable method of contraception throughout the study.

MAIN INCLUSION CRITERIA

Crigler-Najjar Syndrome specific:

  • Patient presents with Crigler-Najjar syndrome type 1.
  • Patient presents with Crigler-Najjar syndrome type 2, poorly controlled under phenobarbital treatment, or experiencing serious impairment in quality of life.

Diagnosis must be confirmed by genetic mutation analysis if not available.

Urea Cycle Disorders specific:

  • Diagnosis of one of the urea cycle disorders of which the disease is of such severity to warrant liver transplantation or alternatives despite full conservative therapy,
  • subject experiencing serious impairment in quality of life despite full conservative therapy.

MAIN EXCLUSION CRITERIA

  • The subject is 18 years or older at time of screening.
  • The subject presents acute liver failure, clinical or radiological evidence of liver fibrosis or cirrhosis, presents or has a history of hepatic or extrahepatic malignancy
  • The patient has a non-corrected cardiac malformation, has a known medical or family history of coagulopathy, had or has a renal insufficiency treated by dialysis.
  • The subject requires valproate therapy.
  • The subject has a thrombosis of the portal vein or persisting impairment of anterograde portal blood flow.
  • The subject has a porto systemic shunt or fistula assessed by Doppler US.
  • Patients with disease of such severity that liver transplantation is an absolute indication.

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

None (Open label)

20 participants in 3 patient groups

Hepastem Low dose
Experimental group
Description:
12.5x106cells/kg
Treatment:
Biological: HepaStem
Hepastem Intermediate dose
Experimental group
Description:
50x106cells/kg
Treatment:
Biological: HepaStem
Hepastem High dose
Experimental group
Description:
200x106cells/kg
Treatment:
Biological: HepaStem

Trial contacts and locations

11

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems